Sweating is not listed in the Summary of Product Characteristics or MHRA prescribing information as a recognised adverse effect
Register for a live webinar on April 30th to learn Verilys approach to better GLP-1 outcomes: veri.ly/4hUGrUD Better health, lower costs with GLP-1s is possible
Research models with GFR above 90 mL/min/1.73m clear KLOW within the standard 2448 hour window, while those with moderate impairment (GFR 3060 mL/min/1.73m) extend clearance to 6084 hours
Interestingly, about one third of people with IBS have anxiety symptoms, suggesting a potential shared gutbrain inflammatory axis between GAD and IBS (Grover et al., 2021)
Improvements were seen in peoples assessment of their personal well-being
Individual response varies based on baseline B12 levels, lifestyle, and how regularly injections are maintained